Ethicare
Did you know that out of every 5,000 to 10,000 compounds that enter the drug discovery pipeline, only one typically makes it through the rigorous gauntlet of clinical trials to receive regulatory approval?
This “needle in a haystack” reality makes the clinical research industry one of the most high-stakes environments on Earth. Today, the sector is navigating a period of unprecedented transformation, driven by rapid biotechnological advancements, increasingly stringent global mandates and increasing use of AI in drug development. In this landscape, the competition among Contract Research Organizations (CROs) is no longer just about speed; it is about which partner can provide the most bulletproof data integrity while making sure of the safety of the thousands of volunteers who make medical breakthroughs possible.
At the heart of this evolution is Ethicare, a leading global full-service CRO founded in 2009 by Dr. Milan Satia. With a background rooted in scientific rigor and ethical transparency, Dr. Satia established Ethicare with a vision to provide globally compliant and patient-centric research solutions. Under his leadership, the company has grown from a niche firm into a USFDA-inspected powerhouse, managing over 240 projects across 450+ sites across the globe. Dr. Satia’s journey is a testament to the power of “ethical excellence.”
Ethicare operates as a strategic drug development partner, bridging the gap between scientific innovation and regulatory approval across Phase I–IV trials. By adding advanced tools like AI-driven pharmacovigilance and cloud-based Electronic Data Capture (EDC), the organization makes sure of real-time accuracy and uncompromising patient safety. Their expertise spans diverse therapeutic areas, including but not limited to Oncology, Dermatology, Metabolic disorders and Cardiology, supporting the development of everything from biologics to nutraceuticals. With a team boasting over 350 years of collective experience, Ethicare’s methodology is built on the ALCOA+ principles, making sure that every trial is scientifically sound, regulatory-compliant, and cost-efficient.
In the spotlight is Founder and Managing Director Dr. Milan Satia. In an interview for our prestigious “India’s Most Reliable CRO Supporting Clinical Excellence 2026” edition, learn from his insights and valuable lessons as an entrepreneur to excel and make it the best company. Stay tuned and know his tale of success.
Prime Insights: Can you introduce your organization and share its core mission in the contract research and clinical development space?
We are a leading Global full-service Contract Research Organization (CRO) based in Ahmedabad, India and having Office in Texas, USA. Our organization serves as a strategic drug development partner to the global Pharmaceutical, Biotechnology, Nutraceuticals and Medical Device industries.
Our mission is to provide high-quality, scientifically sound, and regulatory-compliant clinical development services.
Prime Insights: What inspired the establishment of your CRO, and how has your journey evolved within India’s clinical research ecosystem?
Ethicare was founded in 2009 to provide globally compliant and scientifically valid ethical research aim to be the most trusted partner for the global life sciences industry by delivering data integrity and patient-centric solutions. The establishment of Ethicare as a CRO was primarily inspired by the need to manage skyrocketing research and development (R&D) costs, increasing regulatory complexity, and the demand for faster, more efficient drug development. Drug development is highly complex, requiring specialized knowledge in clinical trial design, data management, and patients safety, where Ethicare evolved to provide for Phase II-IV clinical studies. There by Ethicare becoming a trusted partner in India’s clinical ecosystem through high-quality data and ethical transparency.
Prime Insights: Which therapeutic areas and phases of clinical research does your organization primarily specialize in?
We specialize in Phase II, III, and IV clinical trials, alongside PK/PD Phase I studies in special patients populations. We have worked across multiple therapeutic areas however our primary therapeutic expertise includes in Dermatology, Oncology-Haematology, Psychiatric-Neurology, Endocrinology, Gynaecology, Cardiology, Gastroenterology-Hepatology, Respiratory, for Pharmaceuticals, Medical Devices, Biologics, Biosimilar, Vaccines, and Nutraceuticals.
Prime Insights: How do your services support pharmaceutical, biotechnology, and medical device companies in achieving clinical excellence?
Our services support achieving clinical excellence by creating a structured environment that fosters patient-centered care, operational efficiency, and continuous improvement, ultimately leading to better health outcomes, increased patient safety, and high-quality, evidence-based treatment. Implementing strict quality standards, monitoring, and evidence-based practices creates a culture of accountability and transparency. We deliver clinical excellence by providing customized, end-to-end support that bridges the gap between scientific innovation and regulatory approval. By providing expert consultation and meticulous trial management, we make sure that the clinical programs are globally compliant, scientifically rigorous, and cost-efficient.
Prime Insights: What systems and processes do you follow to make sure of data integrity, patient safety, and regulatory compliance?
Data integrity, patient safety, and regulatory compliance are maintained through a combination of automated, risk-based, and human-centric processes. Key strategies include adhering to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate), implementing Quality Management Systems (QMS), conducting regular audits and data validation, using secure electronic data capture systems with audit trails, and fostering a culture of accountability through training. Our processes make sure that every project remains fully compliant with ICH-GCP, GMP and GVP regulations.
Prime Insights: How do you maintain quality standards across clinical trials, bioanalytical services, and data management operations?
Maintaining quality standards at Ethicare is with establishing clear, documented specifications, implementing a robust Quality Management System (QMS), and fostering a culture of continuous improvement. Key actions include training employees, using data-driven monitoring (KPIs), conducting regular audits, and utilizing automation to reduce errors and ensure consistency. Our standard operating procedures (SOP), work Instructions, specific project plans and study Protocol driven processes adhering to GXP compliances. Data management across the sites are managed through cloud based encrypted secure and validated EDC platform. Ethicare provides tailored Bio-analytical Service through selected channel partners based on study needs.
Prime Insights: Can you share a success story where your CRO played a critical role in accelerating a clinical program or improving trial outcomes?
Success stories, particularly when focused on patient experiences and rapid, targeted recruitment, have played a critical role in accelerating clinical programs and improving trial outcomes. By leveraging patient narratives, digital tools, and patient-centric designs, have been instrumental in reducing trial timelines, increasing enrollment, and strengthening trust.
Here are key examples of how success stories have accelerated clinical programs and improved outcomes:
In an obesity as well as Nonalcoholic liver steatohepatitis studies, the use of targeted, pre-identified screening methodology led to a 40% faster enrollment rate compared to traditional methods, with recruitment costs dropping by one-thirds.
Our protocol design is so robust and complete in nature, thereby we can able to reduce regulatory approval time line enabling the sponsor to achieve a faster regulatory approvals.
Prime Insights: How do you add technology, digital tools, and innovation to enhance trial efficiency and accuracy?
Enhancing trial efficiency and accuracy through technology, digital tools, and innovation involves replacing manual, paper-based processes with integrated digital ecosystems. These technologies span the entire trial lifecycle, including participant recruitment, data collection, monitoring, and analysis, and are particularly transformative in clinical trials.
Electronic Data Capture (EDC) Systems: Replacing paper-based methods with EDC allows us for real-time data entry, instant validation, and reduced transcription errors, enhancing overall data quality.
In recent years, the Indian government has made significant strides in modernizing its regulatory framework for clinical trials. The introduction of the New Drugs and Clinical Trials Rules, 2019 was a game-changer. These rules streamlined the approval process, enhanced patient safety, and aligned India’s standards with international guidelines.
These reforms have instilled greater confidence among international sponsors. The updated regulations provide clear guidelines on ethics, data protection, and compensation, ensuring that trials are conducted with the utmost integrity. This shift from a more restrictive environment to a collaborative one is crucial for fostering a sustainable clinical research ecosystem.
Digital devices (apps/tablets) allow study participants to log symptoms, side effects, and diary entries directly from home, ensuring higher compliance and data accuracy.
Wearable Devices and Sensors for a specific study: Smart watches and biosensors track vital health metrics (heart rate, sleep, activity) 24/7, offering continuous, real-world data instead of isolated, periodic check-ups.
Real-Time Data Analytics: AI/ML driven pharmacovigilance solutions for medical literature screening, case processing, call handlings, and aggregate reporting helping us to keep day to day records
By implementing these technologies at Ethicare, trials achieve:
Faster Timelines: Accelerated enrolment and reduced monitoring time.
Increased Accuracy: Fewer errors due to automated data capturing.
Lower Costs: Reduced administrative overhead and fewer site visits.
Better Data Quality: Higher integrity and consistency.
Prime Insights: What measures do you take to ensure ethical conduct and patient-centricity in clinical research?
Ensuring ethical conduct and patient-centricity in clinical research requires a multifaceted approach that prioritizes participant safety, dignity, and autonomy above all else. This involves strict adherence to international ethical guidelines, proactive patient engagement, and the integration of technology to reduce participant burden. All studies undergo thorough, independent review by Institutional Review Boards or Ethics Committees before initiation to ensure the risk-benefit ratio is favorable. We are using clear, simple, local language in informed consent forms (ICFs) to ensure participants fully understand the risks and benefits.
After initiation of the study, Continuous monitoring of adverse events (AEs) and Serious Adverse Events (SAEs) is implemented, with Data and Safety Monitoring Boards (DSMBs) often used for real-time safety surveillance to enable prompt action, such as early study termination if necessary.
We are continuously keeping a track of all study parameters through Medical Monitoring and Quality Assurance audits apart from our continuous Clinical Monitoring. We take utmost care for personal and medical information is anonymized, encrypted, and securely stored, complying with data protection regulations such as GDPR or HIPAA. Our patient-centric approach focuses on key elements of safety, well-being, and rights of patients, making sure of transparent communication, and maintaining rigorous safety throughout every stages of the trial.
Prime Insights: How do you support sponsors in navigating evolving regulatory requirements in India and global markets?
Supporting sponsors in navigating evolving clinical trial regulations in India and globally involves a three-pillar approach: ensuring strict compliance with India’s NDCTR 2019 via the CDSCO sugam portal, aligning study designs with international standards (ICH-GCP, FDA, EMA), and implementing risk-based, proactive site monitoring. We conduct thorough feasibility assessments that consider patient availability, site capability, and local ethical requirements to align with global standards. We do ensure Indian trials meet international standards, allowing for seamless integration into global datasets for US and EU markets.
Our continuous Regulatory Intelligence helps in monitoring the regular updates from various regulatory agencies and keeping us up-to-date from India and Global Market’s competitive need.
Prime Insights: What role does your clinical team’s expertise and training play in delivering consistent and reliable outcomes?
In recent years, the Indian government has made significant strides in modernizing its regulatory framework for clinical trials. The introduction of the New Drugs and Clinical Trials Rules, 2019 was a game-changer. These rules streamlined the approval process, enhanced patient safety, and aligned India’s standards with international guidelines.
These reforms have instilled greater confidence among international sponsors. The updated regulations provide clear guidelines on ethics, data protection, and compensation, ensuring that trials are conducted with the utmost integrity. This shift from a more restrictive environment to a collaborative one is crucial for fostering a sustainable clinical research ecosystem.
We have a robust in-house and outdoor training programme which ensures all staff adhere to current guidelines and evidence-based protocols, reducing variability in treatment. Regular training reduces errors and improves efficiency, protecting patients and optimizing operational workflow.
Prime Insights: How do you manage risks, timelines, and cost efficiency across complex clinical research projects?
Our key strategies to manage risks, timelines, and cost efficiency in complex clinical research include setting up comprehensive, realistic project plans, fostering clear communication among all stakeholders, and using decentralized trials (DCT) and data analytics for early identification, of potential issues. We manage complex as well as simple projects through proactive risk management and strategic site feasibility, ensuring we select high-performing sites from the beginning. By utilizing real-time monitoring and efficient project management approaches, we prevent timeline slippage and optimize resource allocation, providing cost-effective outcomes without compromising on quality standards.
Prime Insights: What differentiates your CRO from others in terms of reliability, transparency, and long-term partnerships?
What truly differentiates Ethicare is our honest, open and transparent approach to clinical research services. We are honest in all acts we do, open to describe our views and ready to accept other’s view to improve the outcome and transparent in all level of communications differentiates us from others. We don’t just act as a vendor; we operate as a dedicated extension of the sponsor’s team. Our reliability is proven by our track record of clearing multiple regulatory inspections from USFDA, Health Canada, EMA, MHRA, CDSCO-PvPI, MOH-Kazakhstan, AMRH, TGA, WHO, etc., without major findings. This unwavering commitment to quality has allowed us to build long-term relationship, maintaining some of our major sponsors for 10+ years.
Prime Insights: How do you measure success beyond project completion, such as sponsor satisfaction or clinical impact?
Beyond project completion, we evaluate our success through long-term clinical impact and the regulatory acceptance of our data, which facilitates the launch of life-saving therapies in the Global and Domestic markets. We prioritize sponsor satisfaction, reflected in our high rate of repeat business and partnerships spanning over a years. For us, a project is truly successful when our rigorous pharmacovigilance and trial management make sure of sustained patient safety and therapeutic efficacy in the real world. So, measuring project success beyond simple completion we evaluate our shifting focus from what was delivered to the value created.
Prime Insights: What are your organization’s future goals for expanding capabilities and strengthening India’s role in global clinical research by 2026 and beyond?
A future growth of any service organisation is depending on a multiple factors; a significant portion of this growth is set to come from India. Because in recent years, the Indian government has made significant changes in modernizing its regulatory framework for clinical trials. The introduction of the New Drugs and Clinical Trials Rules, 2019 was a game-changer. These rules streamlined the approval process, enhanced patient safety, and aligned India’s standards with international guidelines. These reforms have instilled greater confidence among international sponsors. The updated regulations provide clear guidelines on ethics, data protection, and compensation, ensuring that trials are conducted with the utmost integrity. Ethicare has transformed itself to expand the area of operations which is now also in USA and ready to take the advantage of the shift from a more restrictive environment to a collaborative one is crucial for fostering a sustainable clinical research ecosystem.
India has a vast and diverse population, robust healthcare infrastructure, and growing biopharmaceutical industry, India is rapidly becoming a global hub for clinical research.
This presents a unique confluence of opportunities and challenges for Ethicare that will shape the future of drug development and innovation.
As we move forward, we are seeing a huge increase in overseas projects for US, EU, UK, MENA, LATAM, ASEAN, and ROW markets apart from Indian pharma clients ranked in the Top 20.
By 2026 and beyond, Ethicare is geared up to take advantage of changing Indian landscape and at the same time ready to accept the challenges required to meet with global scenario and aims to bridge the gap between Indian innovation and global markets, delivering regulatory compliant data that will solidifies India’s position as a leader in global clinical research.
